Title 21 Food and Drugs Part 1300 to End
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Aldrich FT-IR Collection Edition I Library
Aldrich FT-IR Collection Edition I Library Library Listing – 10,505 spectra This library is the original FT-IR spectral collection from Aldrich. It includes a wide variety of pure chemical compounds found in the Aldrich Handbook of Fine Chemicals. The Aldrich Collection of FT-IR Spectra Edition I library contains spectra of 10,505 pure compounds and is a subset of the Aldrich Collection of FT-IR Spectra Edition II library. All spectra were acquired by Sigma-Aldrich Co. and were processed by Thermo Fisher Scientific. Eight smaller Aldrich Material Specific Sub-Libraries are also available. Aldrich FT-IR Collection Edition I Index Compound Name Index Compound Name 3515 ((1R)-(ENDO,ANTI))-(+)-3- 928 (+)-LIMONENE OXIDE, 97%, BROMOCAMPHOR-8- SULFONIC MIXTURE OF CIS AND TRANS ACID, AMMONIUM SALT 209 (+)-LONGIFOLENE, 98+% 1708 ((1R)-ENDO)-(+)-3- 2283 (+)-MURAMIC ACID HYDRATE, BROMOCAMPHOR, 98% 98% 3516 ((1S)-(ENDO,ANTI))-(-)-3- 2966 (+)-N,N'- BROMOCAMPHOR-8- SULFONIC DIALLYLTARTARDIAMIDE, 99+% ACID, AMMONIUM SALT 2976 (+)-N-ACETYLMURAMIC ACID, 644 ((1S)-ENDO)-(-)-BORNEOL, 99% 97% 9587 (+)-11ALPHA-HYDROXY-17ALPHA- 965 (+)-NOE-LACTOL DIMER, 99+% METHYLTESTOSTERONE 5127 (+)-P-BROMOTETRAMISOLE 9590 (+)-11ALPHA- OXALATE, 99% HYDROXYPROGESTERONE, 95% 661 (+)-P-MENTH-1-EN-9-OL, 97%, 9588 (+)-17-METHYLTESTOSTERONE, MIXTURE OF ISOMERS 99% 730 (+)-PERSEITOL 8681 (+)-2'-DEOXYURIDINE, 99+% 7913 (+)-PILOCARPINE 7591 (+)-2,3-O-ISOPROPYLIDENE-2,3- HYDROCHLORIDE, 99% DIHYDROXY- 1,4- 5844 (+)-RUTIN HYDRATE, 95% BIS(DIPHENYLPHOSPHINO)BUT 9571 (+)-STIGMASTANOL -
Insomnia and Anxiety in Older People Sleeping Pills Are Usually Not the Best Solution
® Insomnia and anxiety in older people Sleeping pills are usually not the best solution lmost one-third of older people in the people who take one of United States take sleeping pills. These these medicines sleep medicines are also sometimes called only a little longer and A“sedative-hypnotics” or “tranquilizers.” They better than those who affect the brain and spinal cord. don’t take a medicine. Doctors prescribe some of these medicines Sleeping pills can for sleep problems. Some of these medicines have serious side effects. also can be used to treat other conditions, such All sedative-hypnotic medicines have special as anxiety or alcohol withdrawal. Sometimes, risks for older adults. Seniors are likely to be doctors also prescribe certain anti-depressants more sensitive to the medicines’ effects than for sleep, even though that’s not what they’re younger adults. And these medicines may designed to treat. stay in older people’s bodies longer. These Most older adults should first try to treat their medicines can cause confusion and memory insomnia without medicines. According to the problems that: American Geriatrics Society, there are safer and • Increase the risk of falls and hip fractures. better ways to improve sleep or reduce anxiety. These are common causes of hospital stays Here’s why: and death in older people. Sleeping pills may not help much. • Increase the risk of car accidents. Many ads say that sleeping pills help people get a full, restful night’s sleep. But studies show that this is not exactly true in real life. On average, The new “Z” medicines also have risks. -
International Narcotics Control Strategy Report
United States Department of State Bureau for International Narcotics and Law Enforcement Affairs International Narcotics Control Strategy Report Volume I Drug and Chemical Control March 2017 INCSR 2017 Volume 1 Table of Contents Table of Contents Common Abbreviations ............................................................................................................................. iii International Agreements .......................................................................................................................... v INTRODUCTION ........................................................................................................................................... 1 Policy and Program Developments ......................................................................................................... 17 Overview ................................................................................................................................................. 18 Methodology for U.S. Government Estimates of Illegal Drug Production ............................................... 24 (with dates ratified/acceded) ................................................................................................................... 30 USG Assistance ..................................................................................................................................... 36 International Training ............................................................................................................................. -
Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam
Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam Tjiauw-Ling Tan, MD, Edward 0. Bixler, PhD, Anthony Kales, MD, Roger J. Cadieux, MD, and Amy L. Goodman, MD Hershey, Pennsylvania A psychiatric syndrome characterized by agita Sleep Disorders Clinic. He began taking triazolam tion, paranoid ideation, depersonalization, and de at bedtime in a 0.5-mg dose eight months before pression, as well as paresthesias and hyperacusis, his referral. Although the drug was effective ini has been attributed to administration of triazolam tially, tolerance developed, causing the patient to (Halcion).1 The occurrence of these reactions led gradually increase the dosage until eventually he to the removal of the drug from the market in the was taking a total of 1.5 mg nightly. Netherlands. Isolated behavioral side effects that The physical examination revealed no contribu include amnesia2-4 and hallucinations5 have also tory conditions. However, assessment of the pa been reported with administration of triazolam. tient’s mental status revealed that he was extreme Rebound insomnia6 and early morning insom ly guarded and suspicious and preoccupied with nia,7 both associated with increases in daytime his sleeplessness to the degree that this hypochon anxiety,7,8 are withdrawal syndromes known driacal concern had a delusional quality. He also to occur with rapidly eliminated benzodiazepine described two episodes indicating memory impair hypnotics such as triazolam. Rebound insomnia ment; both incidents occurred in the late afternoon consists of a marked increase in wakefulness and involved preparing to eat certain foods, which above baseline levels following drug withdrawal. -
(12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig. -
2020 Kansas Statutes
2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other -
2013 House Judiciary Hb 1070
2013 HOUSE JUDICIARY HB 1070 2013 HOUSE STANDING COMMITTEE MINUTES House Judiciary Committee Prairie Room, State Capitol HB 1070 January 14, 2013 Job #17167 D Conference Committee � · Committee Clerk Signature A-. .;' /) .1� ' I A.J4-��'N'f?4<'71<P2/ I Explanation or reason for introduction of bill/resolution: Relating to the scheduling of controlled substances. Minutes: Chairman Koppelman: Opened the hearing on HB 1070. Mark Hardy, Assistant Executive Director of the NO State Board of Pharmacy: (See testimony #1and 2) He went over these handouts. Rep. Klemin: I don't see an emergency clause in the bill and there is none in the amendment. Did I miss it? Mark Hardy: I want to put an emergency clause on the bill. Rep. Klemin: I think you have to have another section at the end of the bill saying this is an emergency. Rep. Kretschmar: How often do these new drugs come out and should be on it? Mark Hardy: As far as the schedule 1 substances; it is a revolving door and we are always trying to stay in front of what the chemists and what the drug makers are doing. As far as schedule 2 through 5; it is a continuous thing through the DEA. When it becomes a federally controlled substance it takes precedence. Rep. Larson: You have not been aware of the bill I was sponsoring regarding synthetic drugs yet? Mark Hardy: No. The Attorney General briefed me on the Bill #1133. Rep. Larson: The reason for my bill is not get into all of the pharmaceutical names of the chemicals, but anybody that possess or manufacturers a analog in order to try and copy these drugs would be guilty of those offences without having to know the specific chemical compound that might be morphed by unscrupulous people trying to see these products. -
CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1. -
Comparison of Short-And Long-Acting Benzodiazepine-Receptor Agonists
J Pharmacol Sci 107, 277 – 284 (2008)3 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Comparison of Short- and Long-Acting Benzodiazepine-Receptor Agonists With Different Receptor Selectivity on Motor Coordination and Muscle Relaxation Following Thiopental-Induced Anesthesia in Mice Mamoru Tanaka1, Katsuya Suemaru1,2,*, Shinichi Watanabe1, Ranji Cui2, Bingjin Li2, and Hiroaki Araki1,2 1Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan 2Department of Clinical Pharmacology and Pharmacy, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan Received November 7, 2007; Accepted May 15, 2008 Abstract. In this study, we compared the effects of Type I benzodiazepine receptor–selective agonists (zolpidem, quazepam) and Type I/II non-selective agonists (zopiclone, triazolam, nitrazepam) with either an ultra-short action (zolpidem, zopiclone, triazolam) or long action (quazepam, nitrazepam) on motor coordination (rota-rod test) and muscle relaxation (traction test) following the recovery from thiopental-induced anesthesia (20 mg/kg) in ddY mice. Zolpidem (3 mg/kg), zopiclone (6 mg/kg), and triazolam (0.3 mg/kg) similarly caused an approximately 2-fold prolongation of the thiopental-induced anesthesia. Nitrazepam (1 mg/kg) and quazepam (3 mg/kg) showed a 6- or 10-fold prolongation of the anesthesia, respectively. Zolpidem and zopiclone had no effect on the rota-rod and traction test. Moreover, zolpidem did not affect motor coordination and caused no muscle relaxation following the recovery from the thiopental-induced anesthesia. However, zopiclone significantly impaired the motor coordination at the beginning of the recovery. Triazolam significantly impaired the motor coordination and muscle relaxant activity by itself, and these impairments were markedly exacerbated after the recovery from anesthesia. -
Preferred Drug List (PDL) OREGON HEALTH PLAN Trilliumohp.Com
Preferred Drug List (PDL) OREGON HEALTH PLAN TrilliumOHP.com 1-877-600-5472 TTY: 711 MCA_EK16V5 Approved 01/01/2019 OHP-TRIL-17-195 Pharmacy Program Trillium Community Health Plan’s goal is to offer the right drug coverage to our members. We work with doctors and pharmacists to make sure we offer drugs used to treat many conditions and illnesses. Trillium covers prescription and some over the counter drugs when they are ordered by a licensed prescriber. The pharmacy program does not cover all drugs. Some drugs need our prior approval. Some have a limit on the amount of drug that can be given. Sometimes you must get Trillium’s prior approval. Even with approval, we will not pay if you are no longer on OHP or if the treatment isn’t covered by OHP. To be paid, the treatment must follow treatment guidelines. This might include step therapy, meaning trying less costly treatment options first. Medications newly approved by the FDA (Food and Drug Administration) require prior- approval until reviewed by our Pharmacy and Therapeutics Committee. Filling a Prescription You can have your prescriptions filled at a Trillium network pharmacy. At the pharmacy, you will need to give the pharmacist your prescription and your ID card. You can find a pharmacy that is in network by calling a Trillium Member Services Representative at 541-485-2155; Toll Free: 1-877-600-5472, or by using the Find a Provider tool on our website at https://providersearch.trilliumhealthplan.com. You do not have to pay for covered drugs. The Trillium preferred drug list has a large number of brand name and generic drugs on it. -
Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object. -
Surveillance of Drug Abuse Trends in the State of Ohio January - June 2019
OSAMOSAM OhioOhio Substance Substance Abuse Abuse Monitoring Monitoring Network Network SurveillanceSurveillance of of Drug Drug Abuse Abuse Trends Trends in the State of Ohio January - June 2019 Lake Ashtabula Fulton Lucas Williams Ottawa Geauga Cuyahoga Defiance Henry Wood Sandusky Erie Lorain Trumbull Huron Summit Portage Paulding Seneca Medina Putnam Hancock Mahoning Van Wert Wyandot Crawford Ashland Wayne Stark Columbiana Allen Richland Hardin Marion Mercer Auglaize Holmes Carroll Morrow Tuscarawas Jefferson Logan Knox Shelby Union Delaware Coshocton Harrison Champaign Darke Licking Miami Guernsey Belmont Franklin Muskingum Clark Madison Montgomery Preble Fairfield Perry Noble Monroe Greene Pickaway Fayette Morgan Hocking Washington Butler Warren Clinton Ross Athens Vinton Hamilton Highland Clermont Pike Meigs Jackson Brown Adams Scioto Gallia Lawrence Legend Akron-Canton region Columbus region Athens region Dayton region Cincinnati region Toledo region Cleveland region Youngstown region Ohio Substance Abuse Monitoring Network Surveillance of Drug Abuse Trends in the State of Ohio January - June 2019 Prepared by: Ohio Department of Mental Health and Addiction Services Office of Quality, Planning and Research R. Thomas Sherba, OSAM Principal Investigator — PhD, MPH, LPCC Sarah Balser, OSAM Coordinator — MPH, MSW, LSW, CHES Jessica Linley, OSAM Quantitative Data Analyst — PhD, MSW, LSW Table of Contents OSAM-O-Gram....................................................................................................................................................................3